Drug parity legislation: States, organizations seek to make oral cancer drugs more affordable

Cancer

Volumn 120, Issue 3, 2014, Pages 313-314

  Printz, Carrie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB;

CANCER CHEMOTHERAPY; DRUG COST; DRUG LEGISLATION; DRUG MANUFACTURE; GASTROINTESTINAL STROMAL TUMOR; GOVERNMENT REGULATION; HEALTH CARE SYSTEM; HUMAN; MEDICARE; PATENT; PATIENT ADVOCACY; PRESCRIPTION; PRIORITY JOURNAL; PUNISHMENT; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; DRUG COSTS; HUMANS; LEGISLATION, DRUG; MOUTH NEOPLASMS;

EID: 84892915363     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28556     Document Type: Short Survey

References (1)

1. Light DW, Lexchin J, Darrow JJ,. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics. 2013; 41: 590-600.